Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients

Adrian S Dobs, Sam Miller, Gilberto Neri, Stuart Weiss, Ann C. Tate, Deborah R. Shapiro, Thomas A. Musliner

Research output: Contribution to journalArticle

Abstract

Inhibition of cholesterol biosynthesis by hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors could, in theory, adversely affect male gonadal function because cholesterol is a precursor of steroid hormones. The objective of this randomized double-blind trial was to compare the effects of simvastatin, pravastatin, and placebo on gonadal testosterone production and spermatogenesis. After a 6-week placebo and lipid-lowering diet run-in period, 159 male patients aged 21 to 55 years with type IIa or IIb hypercholesterolemia, low-density lipoprotein (LDL) cholesterol between 145 and 240 mg/dL, and normal basal levels of testosterone were randomly assigned to treatment with simvastatin 20 mg (n = 40), simvastatin 40 mg (n = 41), pravastatin 40 mg (n = 39), or placebo (n = 39) once daily. After 24 weeks of treatment, mean total cholesterol levels were decreased 24% to 27% and mean LDL cholesterol was decreased 30% to 34% in the 3 active-treatment groups (P <.001 for all comparisons to placebo). At 24 weeks, there were no statistically significant differences between the placebo group and any of the active-treatment groups for the change from baseline in testosterone, human chorionic gonadotropin (hCG)-stimulated testosterone, free testosterone index, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or sex hormone-binding globulin (SHBG). Moreover, there were no statistically significant differences at week 12 or week 24 for the change from baseline in sperm concentration, ejaculate volume, or sperm motility for any active treatment relative to placebo. Both simvastatin and pravastatin were well tolerated. In summary, we found no evidence for clinically meaningful effects of simvastatin or pravastatin on gonadal testosterone production, testosterone reserve, or multiple parameters of semen quality.

Original languageEnglish (US)
Pages (from-to)115-121
Number of pages7
JournalMetabolism
Volume49
Issue number1
StatePublished - 2000

Fingerprint

Pravastatin
Simvastatin
Testosterone
Placebos
Cholesterol
LDL Cholesterol
Therapeutics
Sex Hormone-Binding Globulin
Semen Analysis
Sperm Motility
Follicle Stimulating Hormone
Chorionic Gonadotropin
Spermatogenesis
Luteinizing Hormone
Hypercholesterolemia
Spermatozoa
Oxidoreductases
Steroids
Hormones
Diet

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Dobs, A. S., Miller, S., Neri, G., Weiss, S., Tate, A. C., Shapiro, D. R., & Musliner, T. A. (2000). Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism, 49(1), 115-121.

Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. / Dobs, Adrian S; Miller, Sam; Neri, Gilberto; Weiss, Stuart; Tate, Ann C.; Shapiro, Deborah R.; Musliner, Thomas A.

In: Metabolism, Vol. 49, No. 1, 2000, p. 115-121.

Research output: Contribution to journalArticle

Dobs, AS, Miller, S, Neri, G, Weiss, S, Tate, AC, Shapiro, DR & Musliner, TA 2000, 'Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients', Metabolism, vol. 49, no. 1, pp. 115-121.
Dobs AS, Miller S, Neri G, Weiss S, Tate AC, Shapiro DR et al. Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism. 2000;49(1):115-121.
Dobs, Adrian S ; Miller, Sam ; Neri, Gilberto ; Weiss, Stuart ; Tate, Ann C. ; Shapiro, Deborah R. ; Musliner, Thomas A. / Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. In: Metabolism. 2000 ; Vol. 49, No. 1. pp. 115-121.
@article{5b91c82df28d49b9a8ccec0822d947df,
title = "Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients",
abstract = "Inhibition of cholesterol biosynthesis by hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors could, in theory, adversely affect male gonadal function because cholesterol is a precursor of steroid hormones. The objective of this randomized double-blind trial was to compare the effects of simvastatin, pravastatin, and placebo on gonadal testosterone production and spermatogenesis. After a 6-week placebo and lipid-lowering diet run-in period, 159 male patients aged 21 to 55 years with type IIa or IIb hypercholesterolemia, low-density lipoprotein (LDL) cholesterol between 145 and 240 mg/dL, and normal basal levels of testosterone were randomly assigned to treatment with simvastatin 20 mg (n = 40), simvastatin 40 mg (n = 41), pravastatin 40 mg (n = 39), or placebo (n = 39) once daily. After 24 weeks of treatment, mean total cholesterol levels were decreased 24{\%} to 27{\%} and mean LDL cholesterol was decreased 30{\%} to 34{\%} in the 3 active-treatment groups (P <.001 for all comparisons to placebo). At 24 weeks, there were no statistically significant differences between the placebo group and any of the active-treatment groups for the change from baseline in testosterone, human chorionic gonadotropin (hCG)-stimulated testosterone, free testosterone index, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or sex hormone-binding globulin (SHBG). Moreover, there were no statistically significant differences at week 12 or week 24 for the change from baseline in sperm concentration, ejaculate volume, or sperm motility for any active treatment relative to placebo. Both simvastatin and pravastatin were well tolerated. In summary, we found no evidence for clinically meaningful effects of simvastatin or pravastatin on gonadal testosterone production, testosterone reserve, or multiple parameters of semen quality.",
author = "Dobs, {Adrian S} and Sam Miller and Gilberto Neri and Stuart Weiss and Tate, {Ann C.} and Shapiro, {Deborah R.} and Musliner, {Thomas A.}",
year = "2000",
language = "English (US)",
volume = "49",
pages = "115--121",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients

AU - Dobs, Adrian S

AU - Miller, Sam

AU - Neri, Gilberto

AU - Weiss, Stuart

AU - Tate, Ann C.

AU - Shapiro, Deborah R.

AU - Musliner, Thomas A.

PY - 2000

Y1 - 2000

N2 - Inhibition of cholesterol biosynthesis by hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors could, in theory, adversely affect male gonadal function because cholesterol is a precursor of steroid hormones. The objective of this randomized double-blind trial was to compare the effects of simvastatin, pravastatin, and placebo on gonadal testosterone production and spermatogenesis. After a 6-week placebo and lipid-lowering diet run-in period, 159 male patients aged 21 to 55 years with type IIa or IIb hypercholesterolemia, low-density lipoprotein (LDL) cholesterol between 145 and 240 mg/dL, and normal basal levels of testosterone were randomly assigned to treatment with simvastatin 20 mg (n = 40), simvastatin 40 mg (n = 41), pravastatin 40 mg (n = 39), or placebo (n = 39) once daily. After 24 weeks of treatment, mean total cholesterol levels were decreased 24% to 27% and mean LDL cholesterol was decreased 30% to 34% in the 3 active-treatment groups (P <.001 for all comparisons to placebo). At 24 weeks, there were no statistically significant differences between the placebo group and any of the active-treatment groups for the change from baseline in testosterone, human chorionic gonadotropin (hCG)-stimulated testosterone, free testosterone index, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or sex hormone-binding globulin (SHBG). Moreover, there were no statistically significant differences at week 12 or week 24 for the change from baseline in sperm concentration, ejaculate volume, or sperm motility for any active treatment relative to placebo. Both simvastatin and pravastatin were well tolerated. In summary, we found no evidence for clinically meaningful effects of simvastatin or pravastatin on gonadal testosterone production, testosterone reserve, or multiple parameters of semen quality.

AB - Inhibition of cholesterol biosynthesis by hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors could, in theory, adversely affect male gonadal function because cholesterol is a precursor of steroid hormones. The objective of this randomized double-blind trial was to compare the effects of simvastatin, pravastatin, and placebo on gonadal testosterone production and spermatogenesis. After a 6-week placebo and lipid-lowering diet run-in period, 159 male patients aged 21 to 55 years with type IIa or IIb hypercholesterolemia, low-density lipoprotein (LDL) cholesterol between 145 and 240 mg/dL, and normal basal levels of testosterone were randomly assigned to treatment with simvastatin 20 mg (n = 40), simvastatin 40 mg (n = 41), pravastatin 40 mg (n = 39), or placebo (n = 39) once daily. After 24 weeks of treatment, mean total cholesterol levels were decreased 24% to 27% and mean LDL cholesterol was decreased 30% to 34% in the 3 active-treatment groups (P <.001 for all comparisons to placebo). At 24 weeks, there were no statistically significant differences between the placebo group and any of the active-treatment groups for the change from baseline in testosterone, human chorionic gonadotropin (hCG)-stimulated testosterone, free testosterone index, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or sex hormone-binding globulin (SHBG). Moreover, there were no statistically significant differences at week 12 or week 24 for the change from baseline in sperm concentration, ejaculate volume, or sperm motility for any active treatment relative to placebo. Both simvastatin and pravastatin were well tolerated. In summary, we found no evidence for clinically meaningful effects of simvastatin or pravastatin on gonadal testosterone production, testosterone reserve, or multiple parameters of semen quality.

UR - http://www.scopus.com/inward/record.url?scp=0033983170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033983170&partnerID=8YFLogxK

M3 - Article

C2 - 10647074

AN - SCOPUS:0033983170

VL - 49

SP - 115

EP - 121

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 1

ER -